{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Armignacco R"],"funding":["Programme Hospitalier de Recherche Clinique “CompliCushing”","Agence Nationale pour la Recherche","European Union's Horizon 2020 research and innovation programme","Else Kröner-Fresenius-Stiftung","Clinical Research Priority Program of the University of Zurich for the CRPP HYRENE","European Union’s Horizon 2020 research and innovation programme","Deutsche Forschungsgemeinschaft (DFG) within the CRC/Transregio 205/1 “The Adrenal: Central Relay in Health and Disease”","Programme Hospitalier de Recherche Clinique \"CompliCushing\""],"pagination":["142"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9635165"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["<h4>Background</h4>Arterial hypertension represents a worldwide health burden and a major risk factor for cardiovascular morbidity and mortality. Hypertension can be primary (primary hypertension, PHT), or secondary to endocrine disorders (endocrine hypertension, EHT), such as Cushing's syndrome (CS), primary aldosteronism (PA), and pheochromocytoma/paraganglioma (PPGL). Diagnosis of EHT is currently based on hormone assays. Efficient detection remains challenging, but is crucial to properly orientate patients for diagnostic confirmation and specific treatment. More accurate biomarkers would help in the diagnostic pathway. We hypothesized that each type of endocrine hypertension could be associated with a specific blood DNA methylation signature, which could be used for disease discriminat"],"journal":["Clinical epigenetics"],"pubmed_title":["Whole blood methylome-derived features to discriminate endocrine hypertension."],"pmcid":["PMC9635165"],"funding_grant_id":["ANR-18-CE14-0008-01","633983","PHRC AOM 12-002-0064","2012_A103 and 2015_A228"],"pubmed_authors":["Bouys L","Reel S","Larsen CK","Williams TA","Januszewicz A","Prejbisz A","Braun L","Gimenez-Roqueplo AP","Kroiss M","Monticone S","Jouinot A","Rossi GP","Mulatero P","Dobrowolski P","Beuschlein F","Scaroni C","Blanchard A","Jefferson E","Zennaro MC","Assie G","Armignacco R","Ceccato F","Perlemoine K","Bertherat J","Septier A","Pecori A","Gaspar C","Reel PS","Amar L","Bonnet-Serrano F","Lenzini L","Riester A","Reincke M","MacKenzie SM","Davies E"],"additional_accession":[]},"is_claimable":false,"name":"Whole blood methylome-derived features to discriminate endocrine hypertension.","description":"<h4>Background</h4>Arterial hypertension represents a worldwide health burden and a major risk factor for cardiovascular morbidity and mortality. Hypertension can be primary (primary hypertension, PHT), or secondary to endocrine disorders (endocrine hypertension, EHT), such as Cushing's syndrome (CS), primary aldosteronism (PA), and pheochromocytoma/paraganglioma (PPGL). Diagnosis of EHT is currently based on hormone assays. Efficient detection remains challenging, but is crucial to properly orientate patients for diagnostic confirmation and specific treatment. More accurate biomarkers would help in the diagnostic pathway. We hypothesized that each type of endocrine hypertension could be associated with a specific blood DNA methylation signature, which could be used for disease discriminat","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T19:53:42.341Z","creation":"2025-02-19T00:31:42.471Z"},"accession":"S-EPMC9635165","cross_references":{"pubmed":["36329530"],"doi":["10.1186/s13148-022-01347-y"]}}